If the company is serious about commercialization, the next several hires should be in the sales and marketing. I would also encourage everyone who has contacts within the company to make their voices heard and demand accurate information. I still am not comfortable with where we are in the process for the EMA and for that matter, the FDA. Why is that? I was encouraged by the one slide regarding Alzheimer’s that showed we hit the end points and P values. I was not encouraged with the Rett information as we have no idea what their intentions are moving forward. I was told that they are going for approvals with Rett based on the data that they have. Why didn’t Doctor Missling state that yesterday? I was also not comfortable with the headcount being at 42. It has been stuck at 42 or in that range forever. I have been told that hiring has been brisk. The 42 number certainly does not show it. I still have complete faith that Anavex will be getting approval for multiple indications possibly late this year. One thing that goes through my mind is that the company is perfectly OK with keeping the share price low so they can continue to reward themselves with stock options until it’s time to let the stock run. Maybe that time comes in the next several months with the peer review. The other issue I have is why hasn’t Wall Street jumped on this company knowing that EMA approval hopefully is coming before the end of the year. Are they thinking that the Rett data is a total failure which we all know is far from the truth, and they correlate that failure in their eyes with Alzheimer’s, being a failure as well? Maybe the only thing that will help us is the FDA allowing us to submit for approval as well. Yes time will tell but the company needs to be more forthcoming with information and the strategy moving forward. I don’t see how keeping things so tight is a competitive advantage at this point in time. If you have the goods go out and shout it from the mountain. Biogen and cassava would be doing it. Especially with the Alzheimer’s results that we have.
Market Data 
Markets 
AI
